Chidamide and sintilimab combination in diffuse large B-cell lymphoma progressing after chimeric antigen receptor T therapy

Table 1 The disease characteristics of 7 patients

Characteristic	Patient
	1	2	3	4	5	6	7
Age (yr)	68	69	60	55	55	46	48
Sex	Male	Male	Male	Female	Female	Female	Female
ECOG PS	1	0	0	1	2	1	0
Diagnosis/subtype	DLBCL (nonGCB)	DLBCL (nonGCB)	DLBCL (nonGCB)	DLBCL (nonGCB)	FL transformed to DLBCL (nonGCB)	DLBCL (nonGCB)	DLBCL (nonGCB)
Disease stage	IVA	IIA	IVB	IVB	IVB	IIIA	IIA
IPI	4	4	4	4	2	4	2
PD-L1 (%)	10	3	0	0	5	0	10
Pre-CAR-T therapies	(1) R2-CHOP; and (2) RCHOP	(1) RCHOP; and (2) RECOP	(1) RCHOP; (2) RGDP; and (3) Ibrutinib	(1) RCHOP	(1) RCHOP; (2) R-DA-EPOCH; (3) R-GeMox; (4) R-ABVD; (5) R2-MTX-CTX; and (6) Ibrutinib	(1) RCHOP; (2) R-DA-EPOCH; and (3) R-Hyper-CVAD	(1) RCHOP; (2) DA-EPOCH; (3) Hyper-CVAD; and (4) AutoHSCT
Response to CART	Relapse after CR post CART	Relapse after PR post CART	No response after CART	Relapse after PR post CART	No response after CART	No response after CART	Relapse after CR post CART
Time from CAR-T to chidamide and sintilimab therapy (mo)	9	4	3	6	3	4	15
Bridging treatment	NO	GDP	ICE	ICE	NO	NO	NO
Response to chidamide and sintilimab therapy	PR	PD	PD	PR	CR	PD	CR

DLBCL: Diffuse large B-cell lymphoma; CAR-T: Chimeric antigen receptor T cells; ICE: Ifosfamide, carboplatin, and etoposide; GDP: Gemcitabine, dexamethasone, cisplatin.